GlassScriptPhysician profile
Luis A Espina
NPI 1396184784
$1,632.63
in general payments reported to CMS, 2019-2025
15 companies · $17.00 in 2025
The $17.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $90.76 · 2021: $364 · 2022: $28.15 · 2023: $55.40 · 2024: $29.05 · 2025: $17.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $101.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $758.00 | 2019 | |
| Novo Nordisk INC | $274.53 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $253.36 | 2021-2022 | |
| Lilly USA, LLC | $79.46 | 2019 | |
| Amarin Pharma, INC. | $68.25 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.97 | 2019 | |
| Glaxosmithkline, LLC. | $30.37 | 2021-2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $23.28 | 2023 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $18.03 | 2023 | Triptodur |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2025 | Jardiance |
| Aytu Biopharma, INC. | $15.51 | 2020 | |
| Eisai INC. | $15.00 | 2021 | |
| Horizon Therapeutics Plc | $13.71 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.77 | 2019 | |
| Abbvie INC. | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Espina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.